New Data from KEYNOTE-028, Merck’s Trial Evaluating KEYTRUDA® (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress
Dateline City:
KENILWORTH, N.J.
Findings Show Anti-Tumor Activity for KEYTRUDA in Two Gastrointestinal Cancers
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced new findings from the KEYNOTE-028 Phase 1b study, the
clinical trial investigating the use of the company’s anti-PD-1 therapy,
KEYTRUDA® (pembrolizumab) in multiple, difficult-to-treat
cancers. Data from this trial, to be presented at the European Cancer
Congress (ECC) in Vienna, Austria, Sept.
Language:
English
Contact:
MerckMedia Contacts:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Gastroenterology | Merck | Politics | Study